

BMJ Open Endoscopic third ventriculostomy for adults with hydrocephalus: creating a prognostic model for success: protocol for a retrospective multicentre study (Nordic ETV)

Sondre Tefre ¹, Alexander Lilja-Cyron ¹, Lisa Arvidsson,² Jiri Bartek ², Alba Corell ³, Axel Forsse ⁴, Andreas Nørgaard Glud ⁵, Sami Abu Hamdeh ⁶, Frederik Lundgaard Hansen,⁵ Antti Huotari ⁷, Conny Johansson ⁸, Olli-Pekka Kämäräinen ⁷, Tommi Korhonen ^{9,10}, Anna Kotkansalo ¹¹, Nadia Mauland Mansoor ¹², Eduardo Erasmo Mendoza Mireles,^{13,14} Rares Miscov ¹⁵, Sune Munthe ¹⁵, Henrietta Nittby-Redebrandt ¹⁶, Nina Obad,¹⁷ Lars Kjelsberg Pedersen,¹⁸ Jussi Posti ¹¹, Rahul Raj ¹⁹, Jarno Satopää ¹⁹, Nils Ståhl,¹⁶ Sami Tetri ^{9,10}, Lovisa Tobieson ²⁰, Marianne Juhler ¹

To cite: Tefre S, Lilja-Cyron A, Arvidsson L, *et al*. Endoscopic third ventriculostomy for adults with hydrocephalus: creating a prognostic model for success: protocol for a retrospective multicentre study (Nordic ETV). *BMJ Open* 2022;**12**:e055570. doi:10.1136/bmjopen-2021-055570

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-055570>).

Received 20 July 2021
Accepted 15 December 2021



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Sondre Tefre;
sondre.tefre@regionh.dk

ABSTRACT

Introduction Endoscopic third ventriculostomy (ETV) is becoming an increasingly widespread treatment for hydrocephalus, but research is primarily based on paediatric populations. In 2009, Kulkarni *et al* created the ETV Success score to predict the outcome of ETV in children. The purpose of this study is to create a prognostic model to predict the success of ETV for adult patients with hydrocephalus. The ability to predict who will benefit from an ETV will allow better primary patient selection both for ETV and shunting. This would reduce additional second procedures due to primary treatment failure. A success score specific for adults could also be used as a communication tool to provide better information and guidance to patients.

Methods and analysis The study will adhere to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis reporting guidelines and conducted as a retrospective chart review of all patients ≥18 years of age treated with ETV at the participating centres between 1 January 2010 and 31 December 2018. Data collection is conducted locally in a standardised database. Univariate analysis will be used to identify several strong predictors to be included in a multivariate logistic regression model. The model will be validated using K-fold cross validation. Discrimination will be assessed using area under the receiver operating characteristic curve (AUROC) and calibration with calibration belt plots.

Ethics and dissemination The study is approved by appropriate ethics or patient safety boards in all participating countries.

Trial registration number NCT04773938; Pre-results.

Strengths and limitations of this study

- Large consecutive sample of adult patients treated with endoscopic third ventriculostomy from multiple neurosurgical centres in the Nordic countries.
- Goal of creating a prognostic model to aid patient selection and guidance.
- Subject to the inherent limitations of a retrospective study.
- Similar healthcare systems in the Nordic countries, and model will need validation in other regions to ensure generalisability.

INTRODUCTION

The most common treatment for hydrocephalus is a ventriculoperitoneal shunt (VPS) to divert excess cerebrospinal fluid (CSF) from the ventricles to be absorbed in the peritoneum. The treatment can be applied in different aetiologies of hydrocephalus, but there is a high complication risk both short and long term.^{1–3} In 2017, Merkler *et al* performed a retrospective review of 17 035 adult patients who had undergone their first VPS surgery for hydrocephalus.² They report that one-third (33.4%) of the patients experienced at least one complication during the follow-up period (3.9 years), and 22% required a shunt revision. Twenty-one per cent of the complications occurred within the first year. Based on 683 adult patients, Reddy

et al reported that 32% experienced shunt failure, with 74% occurring within 6 months.³

Endoscopic third ventriculostomy (ETV) is an alternative treatment option creating a passage between the ventricles and the subarachnoid space by perforating the floor of the third ventricle.⁴ It is minimally invasive and leaves no mechanical foreign body behind, thereby avoiding many of the implant complications associated with VPS.⁵

The overwhelming majority of research on ETV is conducted in paediatric or mixed paediatric/adult populations.^{4,6} In 2009, Kulkarni *et al* created the ETV Success Score (ETVSS) to predict the outcome of ETV treatment in children.⁷ The ETVSS consists of three factors: age, aetiology and shunt history. Based on these factors, a score from 0 to 90 is given, representing the predicted probability of successful ETV outcome 6 months postoperatively.

As the ETVSS is based on paediatric populations and the age differentiation stops after the patient has reached 10 years, 50 out of a possible 90 points are given if the patient is more than 10 years old, making this parameter in the ETVSS redundant when used in adults. Furthermore, the ETVSS does not include several common aetiologies for adult hydrocephalus such as idiopathic and secondary normal pressure hydrocephalus (NPH), subarachnoid haemorrhage (SAH) and long-standing overt ventriculomegaly in adults (LOVA). Previous shunt treatment seems to play an important role in adults as well, but only minimally influences the paediatric score.⁸ Isaacs *et al* reported an overall success rate of 80%. Patients treated with ETV as the primary treatment had a better success rate than previously shunted patients, at 87% and 65%, respectively.⁹ Waqar *et al* showed similar results with 79% success in the primary treatment group and 55% secondary to shunt treatment, at 10 years follow-up of 190 patients.¹⁰

Radiological findings are not included in the ETVSS, and although most radiological signs of obstruction are subjective evaluations based on the observer's experience, some quantifiable signs have been identified. Dlouhy *et al*¹¹ and Kehler *et al*¹² found downward bowing of the third ventricular floor to be a strong predictor of ETV success. The bowing was measured by placing a line through the chiasma to the top of the mesencephalon or the mamillary bodies. Downward bowing was defined as inferior displacement of the third ventricle floor below this line.

Although there are a few studies analysing long-term ETV survival in adults,^{4,9,10} most are in paediatric^{13–19} or mixed populations.^{20–26} The existing long-term series on adult patients show most failures occurring shortly after the procedure although late failures are reported.^{9,10} Kaplan-Meier curves for ETV survival have an initial steep decline, followed by a gradual fall-off before it seems to stabilise with few failures after a certain point. Determining the composition of patient characteristics, these three different parts of the curve could provide insight into how different patient categories respond to ETV.

The initial fall-off is hypothesised to represent patients without benefit from the procedure as well as significant symptoms requiring early reoperation. The second gradual decline might be caused by patients in which the ETV was ineffective from the beginning, but with more chronic symptomatology giving more time to evaluate the effect before reoperation. The failures occurring in the stable part of the curve might represent initial success with a late closure of the stoma or an absorption problem occurring later.

Main hypothesis

A prognostic scoring system for adult ETV can be created based on patient demographics, symptomatology, aetiology, shunt history and radiological findings.

Secondary hypotheses

- ▶ Age is still a relevant factor but has the inverse effect in adults with less successful outcomes with older age.
- ▶ Hydrocephalus aetiology and shunt history have prognostic value but must be recalibrated to reflect the spectrum of hydrocephalus conditions in adults.
- ▶ It is possible to develop a radiological hydrocephalus classification and scoring system providing additional prognostic value.
- ▶ There are different characteristics in the failures occurring during the different phases seen on the Kaplan-Meier survival curve.

Rationale

With ETV becoming an increasingly widespread treatment for adult hydrocephalus,^{9,27} there is a need for a new prognostic model specific for this patient population. The ability to predict who will benefit from an ETV will allow better primary patient selection both for ETV and shunting. This would reduce additional second procedures due to primary treatment failure, and possibly prevent further unnecessary procedures. A success score specific for adults could also be used as a communication tool to provide better information and guidance to patients.

Study goals and objectives

The purpose of this study is to create a prognostic model to predict the short-term success of ETV for adult patients with hydrocephalus.

Specific aims for this research project is to:

1. identify factors associated with both success and failure of ETV in adults, to establish a prognostic model.
2. report on ETV success rates, complications and survival in adult patients at the participating centres.

METHODS AND ANALYSIS

Study design

This is an observational study and will be conducted as a retrospective review of electronic patient charts. The study will adhere to the TRIPOD guidelines in the development of the prediction model.²⁸ A multivariate logistic

regression model will be used to identify prognostic factors for success of ETV treatment. This model is expected to be simplified to include only three to four strong predictors to make it useful in daily clinical practice.

Population

The study will include all patients ≥ 18 years of age treated with ETV at the 19 participating neurosurgical centres in Norway, Sweden, Denmark and Finland from 1 January 2010, to 31 December 2018. Patients are excluded if permanent intraventricular foreign bodies are left behind after the ETV procedure, such as shunts or stents, as they might influence outcome following ETV. Temporary external ventricular drains, ICP-monitoring probes or ligated shunts where the ventricular drain is removed, are not excluded.

Data collection and monitoring

Each of the participating centres will be responsible for the data collection in a standardised database, containing the following information: (see Supplemental material file 1) for full list of variables):

- ▶ Date of birth, sex.
- ▶ Aetiology of hydrocephalus: Haemorrhage (SAH or intraventricular haemorrhage (IVH)), infection or carcinomatosis, tumour or cyst (location), trauma (type of traumatic lesion), malformations (type of malformation), NPH or idiopathic intracranial hypertension (IIH).
- ▶ Radiological investigation: the radiologist's description will be used to determine the presence of a visible obstruction. Specific signs and measurements (see online supplemental material 1) will be recorded based on representative images uploaded to the database. The images will consist of one mid-sagittal, coronal (at the level of the posterior commissure) and axial (at the level of the frontal horns widest point). These images will be reviewed in bulk, with assistance from the Department for Neuroradiology in Copenhagen.
- ▶ Previous shunt treatment: number of revisions, cause of malfunction, year of first shunt.
- ▶ Preoperative symptoms: acute and chronic symptoms, including preoperative GCS.
- ▶ Surgical details: date, perioperative observation, concurrent and following procedures.
- ▶ Complications: perioperative and postoperative complications, length of stay, permanent morbidity and mortality.
- ▶ Follow-up: clinical status at first postoperative follow-up at 3–12 months, as well as most recent follow-up for ETV durability. Clinical improvement will be registered based on the records from the first available follow-up. If the patient's chart leaves any doubt when registering if the patient's symptoms improved postoperatively, it should be registered as 'not improved'.




Figure 1 Definition of short-term endoscopic third ventriculostomy (ETV) success. Results of re-ETV is not counted in the overall success rate. CSF, cerebrospinal fluid.

All ETVs performed at the participating centres will be entered in the database and then included or excluded based on the inclusion/exclusion criteria. Reason for exclusion will be registered.

Definition of ETV-success

Success is defined as no need for further CSF-diversion procedures within the first year of follow-up (figure 1). Patients in whom the ETV was deemed ineffective before the patient was discharged or where a second procedure was performed during the same admission are included in the registry. Implantation of ICP-monitoring equipment does not render the ETV unsuccessful, unless it is followed by CSF diversion. Patients undergoing repeat ETV are counted as failures when calculating the success rate, but results are registered in order to determine the efficacy of re-ETVs. Additional CSF-diversion procedures will be registered for the entire observation period (beyond the first year) to determine long-term ETV survival.

Sample size

Sample size was calculated using the 'pmsampsize' package in R by Riley *et al.*²⁹ The closest analogous predictive model is the ETVSS by Kulkarni *et al.*⁷ and the estimation was created using prevalence and C-statistic from this model. This resulted in a minimum sample size of 429 patients, for a predictive model using 5 variables. There is no upper limit, as more patients would give a

better foundation for the prediction model, especially in patients with aetiologies rarely treated with ETV such as iNPH or hydrocephalus caused by infection or SAH. Approximately 220 adult ETV patients have been identified in Copenhagen 2010–2017. Cooperation between several centres should easily provide the minimum required sample size and the necessary power to create a robust prognostic model. An estimate of at least 250 ETV procedures from each of the participating countries would result over 1000 patients.

Follow-up

This is a retrospective study, and thus limited to the information documented in the patient records.

Clinical status is registered at first postoperative follow-up at 3–12 months, as well as most recent follow-up where ETV durability can be assessed. The study population will be followed up on in the future to determine long term outcomes, but this is beyond the scope of this study.

Data management and statistical analysis

Patient demographics, hydrocephalus aetiology and shunt history, as well as complications, will be summarised using descriptive statistics. The patient's symptoms are categorised as 'improved' or 'not improved' following treatment. If the patient requires subsequent CSF diversion procedures the ETV is considered a failure. Each of the proposed predictors is analysed in a univariate statistical analysis and are subsequently included in a multivariate logistic regression model to construct a unified prediction model. Statistical significance is defined at $p < 0.05$. The model will be validated using K-fold cross validation. Discriminative ability will be assessed using area under the receiver operating characteristic curve (AUROC) and calibration using calibration belt plots.³⁰ Significant missing data will be handled using multiple imputation.³¹ Time to ETV failure will be analysed using Kaplan-Meier curves.

Outcome variables

Primary outcome

- ▶ Short-term ETV success rate defined as no need for further CSF-diversion procedures within the first year of follow-up.

Secondary outcomes

- ▶ Rate of clinical improvement at first follow-up following ETV, and correlation with need for eventual CSF diversion.
- ▶ Time to failure: examined using Kaplan-Meier analysis.
- ▶ Complications, all registered intraoperative and post-operative complications and deficits, assessed up to 3 months postoperatively.

Creating a prognostic model for adults based on a large population will improve the ability to predict the outcome of ETV and offer the appropriate treatment. The goal is to increase the benefit for patients and reduce

the number of unnecessary procedures. The model will need to be tested in a future prospective study. And a later follow-up with the population in this study to report long term outcomes.

Project status

At the time of the submission of the protocol, data collection has started at all participating sites.

Duration of the project

Data collection is expected to be completed by May 2022, data analysis during Q2 of 2022 and publication Q3 2022.

Patient and public involvement

The study is observational based on retrospective data. No patients were involved in the design or implementation of the study.

Data sharing plan

The study is conducted as part of the Nordic Young Neurosurgeons Research Collaborative (NYNReC). Data are available on reasonable request. Interested parties must apply in writing through nynrec.org including plan for analysis and dissemination of findings. Application will be evaluated by the NYNReC Committee and study lead. A request for access may be declined if the proposal lacks clarity or a satisfactory methodology.

SAFETY AND ETHICAL CONSIDERATIONS

The study is retrospective, based on electronic patient records, and will not intervene in patient treatment in any way. The main concern is data protection and privacy, and the study is approved by appropriate ethics or patient safety boards in all participating countries:

- ▶ Norway: Regional Committees for Medical and Health Research Ethics (REC): 90 565.
- ▶ Sweden: Swedish Ethical Review Authority: 2020-00874.
- ▶ Denmark: Danish Patient Safety Authority: 3-3013-2335/1 and 31-1522-58; Knowledge Center for Data Reviews (Videnscenter for Dataanmeldelser): P-2020-569.
- ▶ Finland: FINDATA—Social and Health Data Permit Authority: THL/2288/14.02.00/2000.

The study has been registered on clinicaltrials.gov under prior to the start of data collection.

Author affiliations

¹Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark

²Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden

³Department of Neurosurgery, Sahlgrenska University Hospital, Goteborg, Sweden

⁴Department of Neurosurgery, Odense University Hospital, Odense, Denmark

⁵Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark

⁶Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden

⁷Department of Neurosurgery NeuroCenter, Kuopio University Hospital, Kuopio, Pohjois-Savo, Finland

⁸Department of Neurosurgery, University Hospital of Umeå, Umeå, Sweden

⁹Department of Neurosurgery, Oulu University Hospital, Oulu, Finland

¹⁰Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland

- ¹¹Department of Neurosurgery and Brain Injury Centre, Turku University Hospital, Turku, Finland
- ¹²Department of Neurosurgery, St Olavs Hospital Universitetssykehuset i Trondheim, Trondheim, Trøndelag, Norway
- ¹³Department of Neurosurgery, Oslo University Hospital Ullevaal, Oslo, Norway
- ¹⁴Department of Neurosurgery, Rikshospitalet University Hospital, Oslo, Norway
- ¹⁵Department of Neurosurgery, Aalborg University Hospital, Aalborg, North Denmark Region, Denmark
- ¹⁶Department of Neurosurgery, Lund University Hospital, Lund, Sweden
- ¹⁷Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway
- ¹⁸Department of Neurosurgery, University Hospital of North Norway, Tromsø, Norway
- ¹⁹Department of Neurosurgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
- ²⁰Department of Neurosurgery in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Östergötland, Sweden

Contributors Study initiation and design, protocol draft preparation: SoT, AL-C and MJ. Data collection: SoT, LA, JB, AC, AF, ANG, SAH, FLH, AH, CJ, O-PK, TK, AK, NMM, EEMM, RM, SM, HN-R, NO, LKP, JP, RR, JS, NS, SaT and LT. All authors reviewed and approved the final version of the protocol.

Funding As this is a retrospective chart review, limited funds are required. SoT has been partially funded by the Lundbeck Foundation (F-22218-19) and the Hjerne- og Nervekirurgisk Forskningspulje, Rigshospitalet (F23026-02, N497). No other specific funding has been received for this study.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Sondre Tefre <http://orcid.org/0000-0002-9516-4440>

Alexander Lilja-Cyron <http://orcid.org/0000-0003-2915-249X>

Jiri Bartek <http://orcid.org/0000-0002-2911-1914>

Alba Corell <http://orcid.org/0000-0002-6329-2392>

Axel Forsse <http://orcid.org/0000-0002-0325-0262>

Andreas Nørgaard Glud <http://orcid.org/0000-0003-3339-6120>

Sami Abu Hamdeh <http://orcid.org/0000-0001-6173-8357>

Antti Huotari <http://orcid.org/0000-0002-7212-5780>

Conny Johansson <http://orcid.org/0000-0001-8612-7173>

Olli-Pekka Kämäräinen <http://orcid.org/0000-0002-6111-3725>

Tommi Korhonen <http://orcid.org/0000-0002-5500-9200>

Anna Kotkansalo <http://orcid.org/0000-0002-3182-7786>

Nadia Mauland Mansoor <http://orcid.org/0000-0001-5668-3275>

Rares Miscov <http://orcid.org/0000-0003-0302-3497>

Sune Munthe <http://orcid.org/0000-0002-4793-9803>

Henrietta Nittby-Redebrandt <http://orcid.org/0000-0003-0140-8107>

Jussi Posti <http://orcid.org/0000-0002-5925-5193>

Rahul Raj <http://orcid.org/0000-0003-4243-9591>

Jarno Satopää <http://orcid.org/0000-0002-2674-0301>

Sami Tetri <http://orcid.org/0000-0002-1387-9136>

Lovisa Tobieson <http://orcid.org/0000-0003-2284-846X>

Marianne Juhler <http://orcid.org/0000-0003-2652-7495>

REFERENCES

- Reddy GK, Bollam P, Caldito G, *et al.* Ventriculoperitoneal shunt complications in hydrocephalus patients with intracranial tumors: an analysis of relevant risk factors. *J Neurooncol* 2011;103:333–42.
- Merkler AE, Ch'ang J, Parker WE, *et al.* The rate of complications after ventriculoperitoneal shunt surgery. *World Neurosurg* 2017;98:654–8.
- Reddy GK, Bollam P, Shi R, *et al.* Management of adult hydrocephalus with ventriculoperitoneal shunts: long-term single-institution experience. *Neurosurgery* 2011;69:774–81.
- Grand W, Leonardo J, Chamczuk AJ, *et al.* Endoscopic third ventriculostomy in 250 adults with hydrocephalus: patient selection, outcomes, and complications. *Neurosurgery* 2016;78:109–19.
- Bouras T, Sgouros S. Complications of endoscopic third ventriculostomy. *J Neurosurg* 2011;7:643–9.
- Dusick JR, McArthur DL, Bergsneider M. Success and complication rates of endoscopic third ventriculostomy for adult hydrocephalus: a series of 108 patients. *Surg Neurol* 2008;69:5–15.
- Kulkarni AV, Drake JM, Mallucci CL, *et al.* Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus. *J Pediatr* 2009;155:254–9.
- Foley RW, Nodoro S, Crimmins D, *et al.* Is the endoscopic third ventriculostomy success score an appropriate tool to inform clinical decision-making? *Br J Neurosurg* 2017;31:314–9.
- Isaacs AM, Bezchlibnyk YB, Yong H, *et al.* Endoscopic third ventriculostomy for treatment of adult hydrocephalus: long-term follow-up of 163 patients. *Neurosurg Focus* 2016;41:E3.
- Waqar M, Ellenbogen JR, Stovell MG, *et al.* Long-Term outcomes of endoscopic third ventriculostomy in adults. *World Neurosurg* 2016;94:386–93.
- Dlouhy BJ, Capuano AW, Madhavan K, *et al.* Preoperative third ventricular bowing as a predictor of endoscopic third ventriculostomy success. *J Neurosurg Pediatr* 2012;9:182–90.
- Kehler U, Regelsberger J, Gliemroth J, *et al.* Outcome prediction of third ventriculostomy: a proposed hydrocephalus grading system. *Minim Invasive Neurosurg* 2006;49:238–43.
- Breimer GE, Sival DA, Bruske-Keizer MGJ, *et al.* An external validation of the ETSS for both short-term and long-term predictive adequacy in 104 pediatric patients. *Childs Nerv Syst* 2013;29:1305–11.
- Durnford AJ, Kirkham FJ, Mathad N, *et al.* Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus: validation of a success score that predicts long-term outcome. *J Neurosurg Pediatr* 2011;8:489–93.
- Hong S, Hirokawa D, Usami K, *et al.* The long-term outcomes of endoscopic third ventriculostomy in pediatric hydrocephalus, with an emphasis on future intellectual development and shunt dependency. *J Neurosurg Pediatr* 2018;23:104–8.
- Dewan MC, Lim J, Shannon CN, *et al.* The durability of endoscopic third ventriculostomy and ventriculoperitoneal shunts in children with hydrocephalus following posterior fossa tumor resection: a systematic review and time-to-failure analysis. *J Neurosurg Pediatr* 2017;19:578–84.
- Stovell MG, Zakaria R, Ellenbogen JR, *et al.* Long-Term follow-up of endoscopic third ventriculostomy performed in the pediatric population. *J Neurosurg* 2016;17:734–8.
- Faggini R, Calderone M, Denaro L, *et al.* Long-Term operative failure of endoscopic third ventriculostomy in pediatric patients: the role of cine phase-contrast MR imaging. *Neurosurg Focus* 2011;30:E1.
- Beuriat P-A, Puget S, Cinalli G, *et al.* Hydrocephalus treatment in children: long-term outcome in 975 consecutive patients. *J Neurosurg Pediatr* 2017;20:10–18.
- Sacko O, Boetto S, Lauwers-Cances V, *et al.* Endoscopic third ventriculostomy: outcome analysis in 368 procedures. *J Neurosurg Pediatr* 2010;5:68–74.
- Kadrian D, van Gelder J, Florida D, *et al.* Long-Term reliability of endoscopic third ventriculostomy. *Neurosurgery* 2005;56:1271–8.
- Gangemi M, Mascari C, Maiuri F, *et al.* Long-Term outcome of endoscopic third ventriculostomy in obstructive hydrocephalus. *Minim Invasive Neurosurg* 2007;50:265–9.
- Vulcu S, Eickele L, Cinalli G, *et al.* Long-Term results of endoscopic third ventriculostomy: an outcome analysis. *J Neurosurg* 2015;123:1456–62.
- Vogel TW, Bahuleyan B, Robinson S, *et al.* The role of endoscopic third ventriculostomy in the treatment of hydrocephalus. *J Neurosurg* 2013;12:54–61.
- Rahme R, Rahme RJ, Hourani R, *et al.* Endoscopic third ventriculostomy: the Lebanese experience. *Pediatr Neurosurg* 2009;45:361–7.
- Gliemroth J, Käsbeck E, Kehler U. Ventriculocisternostomy versus ventriculoperitoneal shunt in the treatment of hydrocephalus: a

- retrospective, long-term observational study. *Clin Neurol Neurosurg* 2014;122:92–6.
- 27 Woodworth GF, See A, Bettgowda C, *et al*. Predictors of surgery-free outcome in adult endoscopic third ventriculostomy. *World Neurosurg* 2012;78:312–7.
- 28 Collins GS, Reitsma JB, Altman DG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ* 2014;350.
- 29 Riley RD, Ensor J, Snell KIE, *et al*. Calculating the sample size required for developing a clinical prediction model. *BMJ* 2020;368:m441.
- 30 Nattino G, Finazzi S, Bertolini G. A new test and graphical tool to assess the goodness of fit of logistic regression models. *Stat Med* 2016;35:709–20.
- 31 Pedersen AB, Mikkelsen EM, Cronin-Fenton D, *et al*. Missing data and multiple imputation in clinical epidemiological research. *Clin Epidemiol* 2017;9:157–66.

Endoscopic Third Ventriculostomy for Adults with Hydrocephalus: Creating a Prognostic Model for Success – Protocol for a Retrospective Multicentre Study (Nordic ETV)

Supplementary Material 1: List of Variables

Variable / Field name	Field Label	Field Attributes (Field Type, Validation, Choices, Calculations, etc.)
Instrument: Data Entry Form (for local data collection)		
record_id	Record ID	Text
location_country	Country	Radio buttons: 1. Norway 2. Sweden 3. Denmark 4. Finland
location_no	Where in Norway was the ETV performed?	Radio buttons: 1. Bergen 2. Oslo – Ullevål 3. Oslo – Rikshospitalet 4. Tromsø 5. Trondheim
location_swe	Where in Sweden was the ETV performed?	Radio buttons: 1. Stockholm 2. Lund 3. Linköping 4. Gothenburg 5. Uppsala 6. Umeå
location_dk	Where in Denmark was the ETV performed?	Radio buttons: 1. Copenhagen 2. Odense 3. Århus 4. Ålborg
location_fin	Where in Finland was the ETV performed?	Radio buttons: 1. Helsinki 2. Tampere 3. Kuopio 4. Turku 5. Oulu
date_of_birth	Date of Birth	Date
sex	Sex	Radio buttons: 1. Female 2. Male
History and Aetiology		
patient_group	Patient group - Estimated or defined time of hydrocephalus onset, in relation to age.	1. Child - diagnosed during childhood with congenital or early acquired hydrocephalus 2. Adult - diagnosed during childhood with congenital or early acquired hydrocephalus 3. Adult - diagnosed as an adult, presumably with a congenital or early acquired hydrocephalus 4. Adult diagnosed as an adult with acquired hydrocephalus
aetiol	Aetiology of hydrocephalus	1. Non-traumatic haemorrhage 2. Infection 3. Neoplasm or cyst 4. Trauma 5. Malformation 6. Other
aetiol_haem	What type of haemorrhage? (If haemorrhagic aetiology)	1. SAH 2. IVH 99. Other
aetiol_infect	What type of infection? (If infectious aetiology)	1. Meningitis 2. Abscess 99. Other
aetiol_tumour	Where is the tumour located? (If tumoural aetiology)	1. Third ventricle 2. Fourth ventricle 3. Cerebellum 4. Cerebellopontine angle 5. Tectal plate tumour 6. Pineal tumour 99. Other
aetiol_trauma	Type of traumatic lesion? (If traumatic aetiology)	Checkbox: 1. aetiol_trauma__1 Contusions 2. aetiol_trauma__2 Traumatic SAH 3. aetiol_trauma__3 SDH

Endoscopic Third Ventriculostomy for Adults with Hydrocephalus: Creating a Prognostic Model for Success – Protocol for a Retrospective Multicentre Study (Nordic ETV)

		4. aetiolo_trauma__4 IVH 5. aetiolo_trauma__5 DAI 99. aetiolo_trauma__99 Other
aetiolo_cong	What type of malformation? (If congenital or early acquired aetiology)	Radio buttons: 1. Aqueductal stenosis 2. Chiari malformation 3. Dandy-Walker malformation 4. LOVA 99. Other
aetiolo_idio	Diagnosis? (If other aetiology)	Radio buttons: 1. iNPH 2. IIH 99. Other
aetiolo_other	Other aetiology	Text
Radiology		
visible_obstruct	Documented obstruction? In radiologists description	Yes/No
visible_obstruct_loc	Where was the obstruction?	Radio buttons: 1. Foramen monroi 2. Third ventricle 3. Aqueductus sylvii 4. Fourth ventricle 99. Other extraventricular obstruction
visible_obstruct_loc_o ther	Describe the location of the obstruction. If other obstruction.	Text
sagittal_upload	Upload mid-sagittal image	File
axial_upload	Upload axial image at the level of the frontal horns widest point	File
coronal_upload	Upload coronal image at the level of the posterior commissure	File
Symptoms		
symptoms	Preoperative symptoms	checkbox 1. symptoms__1 Headache 2. symptoms__2 Nausea/Vomiting 3. symptoms__3 Dizziness 4. symptoms__4 Visual symptoms 5. symptoms__5 GCS < 15 6. symptoms__6 Cognitive Decline 7. symptoms__7 Gait Imparement 8. symptoms__8 Urinary Problems 99. symptoms__99 Other
gcseye	GCS: Eye opening	Text
gcsverbal	GCS: Verbal response	Text
gcsmotor	GCS: Motor response	Text
gcs	Preoperative GCS score	Text
symptoms_other	Other symptoms	Text
Shunt History		
shunt	Previous shunt treatment	Yes/No
shunt_year	Year of first shunt procedure?	Text (integer)
shunt_failure	Cause of shunt failure? Reason for shunt dysfunction leading up to ETV.	Radio buttons 1. Obstruction 2. Infection 3. Overdrainage 4. Disconnection 99. Other
shunt_failure_other	Other cause of shunt failure	Text
shunt_revision	Previous shunt revisions Check "Yes" if the patient has had one or more shunt revisions prior to their ETV.	Yes/No
shunt_revision_nr	Number of revisions	1. 1 2. 2-5 3. 6-10 4. 11-20 5. >20 88. Not reported
ETV Procedure		
etv_date	Date of ETV procedure	Date
etv_age_cal	Calculated age at ETV Procedure	Calculation: rounddown(datediff ([date_of_birth], [etv_date], "y", "dmy"),0)
perop_obs	Peroperative observations	Checkbox: 1. perop_obs__1 Opaque floor of the third ventricle

Endoscopic Third Ventriculostomy for Adults with Hydrocephalus: Creating a Prognostic Model for Success – Protocol for a Retrospective Multicentre Study (Nordic ETV)

		2. perop_obs__2 Prepontine membranes 3. perop_obs__3 Pulsations of the stoma 77. perop_obs__77 None 88. perop_obs__88 Not reported 99. perop_obs__99 Other
perop_obs_other procedures	Other peroperative observations Was any of the following procedures performed at the time of ETV?	Checkbox: 1. procedures__1 Tumor biopsy 2. procedures__2 External ventricular drain (EVD) 3. procedures__3 Stent (in third ventricle floor or the aqueduct) 4. procedures__4 Shunt 5. procedures__5 ICP monitoring probe 6. procedures__6 Fenestration of preponine membranes 88. procedures__88 Not reported 99. procedures__99 Other
other_procedures	What other procedures?	Text
shunt_handling	How was the existing shunt handled?	Checkbox shunt_handling__1 Removed during same procedure. shunt_handling__2 Removed prior to ETV procedure. shunt_handling__3 Left in situ. shunt_handling__4 Ligated and left in situ. shunt_handling__5 Ligated and removed ventricular drain. shunt_handling__88 Not reported shunt_handling__99 Other
shunt_handling_other	Please specify how the existing shunt was handled	Text
re_proced	Subsequent CSF-diversion procedure	Radio buttons: 1. None 2. Shunt treatment 3. Repeat ETV
re_procedure_date	Date of second procedure	Date
re_procedure_time_c alc	Calculated time between first and second procedure (months)	Calculation: round(datediff([etv_date], [re_procedure_date], "M", "dmy"),2)
improvement_re_etv	Clinical state at first follow up after reETV? If there is any doubt if the patient has improved or not at follow up select "Not improved".	Radio buttons: 1. Improved 2. Not improved
re_proced_2	Subsequent CSF-diversion procedure	Radio buttons: 4. None 5. Shunt treatment 6. Repeat ETV
Complications and Mortality		
compl	Complications	Yes/No
intraop_compl	Perioperative complications	Checkbox: 1. intraop_compl__1 Haemorrhage 2. intraop_compl__2 Structural lesion 99. intraop_compl__99 Other
postop_compl	Postoperative complications	Checkbox: 1. postop_compl__1 Intracranial haematoma (EDH or SDH) 2. postop_compl__2 Wound infection 3. postop_compl__3 CNS infection 4. postop_compl__4 CSF leak 5. postop_compl__5 Thromboembolic (DVT or PE) 6. postop_compl__6 Sepsis 99. postop_compl__99 Other
compl_other	Other complications	Text
discharge_date	Date of discharge from a neurosurgical or neurological department.	Date
length_of_stay	length_of_stay	Calculation: rounddown(datediff([etv_date], [discharge_date], "d", "dmy"),0)
morbidity	Permanent morbidity. Did the patient suffer permanent morbidity in relation to the procedure?	Yes/No
morbidity_describe	What kind of morbidity? Describe the nature of the permanent deficits.	Text
mors	Procedure related mortality. Did the patient die in relation to the ETV procedure?	Yes/No

Endoscopic Third Ventriculostomy for Adults with Hydrocephalus: Creating a Prognostic Model for Success – Protocol for a Retrospective Multicentre Study (Nordic ETV)

mors_date	When did the patient die?	Date
mors_cause	How did the patient die? Describe the cause and time of death, in relation to the procedure.	Text
Follow-Up		
first_follow_up_date	Date of first follow-up?	Date
first_follow_up_calc	Calculated time to first follow-up (months)	Calculation: round(datediff([etv_date], [first_follow_up_date], "M", "dmy"),2)
clinical_state_follow_up	Clinical state at first follow up? If there is any doubt if the patient has improved or not at follow up select "Not improved".	Radio buttons 1. Improved 2. Not improved
success	Was the ETV procedure a success or failure?	Radio buttons 1. Success 0. Failure
recent_follow_up_date	Most recent follow-up date ETV Success: Set the date to most recent follow up. ETV failure: Set the date to when it was realized the ETV was unsuccessful.	Date
recent_follow_up_calc	Calculated follow up duration (months)	Calculation: round(datediff([etv_date], [recent_follow_up_date], "M", "dmy"),2)

Variable / Field name	Field Label	Field Attributes (Field Type, Validation, Choices, Calculations, etc.)
Instrument: Radiological Measurements (completed based on uploaded images)		
callosal_angle	Callosal angle	Text
temporal_horns	Dilated temporal horns	Yes/No
third_ventricle_bow	Downward bowing of third ventricle floor?	Yes/No
recesses	Ballooning of the recesses of the third ventricle	Yes/No
corpus_callosum	Thinned and/or elevated corpus callosum	Yes/No
dilated_aqueduct	Dilated aqueduct	Yes/No
radiol_obstruct_sign_other	What other radiological signs are present?	Text